Table 2. Clinico-biological, radiological and therapeutic characteristics of HCC patients at HUJRB (n = 42).
| Variables | N (%) |
|---|---|
| Smoking, Yes/no | 29 (69.05)/13 (30.95) |
| Revealing symptomatology’s | |
| Abdominal pain | 16 (38.10) |
| Alteration of the general sate | 1 (2.38) |
| Decompensation of cirrhosis | 18 (42.85) |
| Jaundice | 5 (11.90) |
| Abdominal mass | 2 (4.76) |
| PSI, 0/1–2/>2 | 5 (11.90)/18 (42.86)/19 (45.24) |
| AFP level (ng/mL) | |
| <200 | 8 (19.05) |
| 200–500 | 8 (19.05) |
| >500 | 26 (61.90) |
| Total bilirubin (μmol/L), <20/20–30/>30 | 4 (9.52)/15 (35.71)/23 (54.76) |
| ALT (U/L), ≤45/>45 | 5 (11.90)/37 (88.10) |
| Cirrhosis, Yes/no | 42 (100)/0 (0) |
| Child–Pugh class, A/B/C | 4 (9.52)/23 (54.76)/15 (35.71) |
| Aetiological factors | |
| HBV | 18 (42.86) |
| HCV | 8 (19.05) |
| HBV/HCV | 3 (7.14) |
| Alcohol | 10 (23.81) |
| Cryptogenic | 3 (7.14) |
| Nodule size (cm), <3/3–5/>5 | 18 (42.86)/14 (33.33)/10 (23.81) |
| Number of nodule, Single/multiple (≥2) | 9 (21.43)/33 (78.57) |
| Stage of tumour | |
| Localised | 23 (54.76) |
| Locoregional invasion | 16 (38.10) |
| Distant metastasis | 3 (7.14) |
| Portal thrombosis, Yes/no | 6 (14.29)/36 (85.71) |
| BCLC stages | |
| A | 1 (2.38) |
| B | 0 (0) |
| C | 20 (47.62) |
| D | 21 (50) |
| Treatments | |
| Curative | 1 (2.38) |
| Palliative | 41 (97.62) |
AFP, α-foetoprotein; ALT, Alanine aminotransferase; HBV, Hepatitis B virus infection; HCV, Hepatitis C virus infection; BCLC, Barcelona Clinic Liver Cancer